Clavis Pharma is focused on leveraging its Lipid Vector Technology to develop of a strong pipeline of proprietary new and improved cancer drugs
LVT derivatives of a range of anti-cancer drugs, such as nucleosides, anthracyclines and taxanes, have been prepared and screened in vitro and in vivo. Improved activity, enhanced cellular uptake, a better toxicity profile and the possibility of alleviating certain drug resistance mechanisms have all been demonstrated in one or more of the LVT derivatives.
|
Clavis Pharma oncology research pipeline |
|||
|
Compound class |
Approx. no. compounds |
In vitro results |
In vivo results |
|
Nucleosides |
22* |
V |
V |
|
Alkylating agents |
4 |
V |
V |
|
Anthracyclines |
7 |
V |
V |
|
Microtubule targeting agents |
6 |
V |
V |
|
Others |
8 |
V |
|
|
|
|
|
|
* Ara-C and gemcitabine derivatives not included